Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma

Clinical Cancer Research

Volumn 24, Issue 19, 2018, Pages 4650-4661

  Lim, Ho Yeong ^a,ac   Merle, Philippe ^b   Weiss, Karl Heinz ^c   Yau, Thomas ^d   Ross, Paul ^e   Mazzaferro, Vincenzo ^f   Blanc, Jean Fredèric ^g   Ma, Yuk Ting ^h   Yen, Chia Jui ⁱ   Kocsis, Judit ^j   Choo, Su Pin ^k   Sukeepaisarnjaroen, Wattana ^l   Gerolami, Rene ^m   Dufour, Jean François ⁿ   Gane, Edward J ^o   Ryoo, Baek Yeol ^p   Peck Radosavljevic, Markus ^q,ab   Dao, Thong ^r   Yeo, Winnie ^s   Lamlertthon, Wisut ^t   Thongsawat, Satawat ^u   Teufel, Michael ^v   Roth, Katrin ^w   Reis, Diego ^x   Childs, Barrett H ^v   Krissel, Heiko ^w   Llovet, Josep M ^y,z,aa   more..

^a Sungkyunkwan University   (South Korea)

^b CROIX ROUSSE HOSPITAL   (France)

^c Liver Cancer Center Heidelberg   (Germany)

^d QUEEN MARY HOSPITAL   (Hong Kong)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF MILAN   (Italy)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

ⁱ NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^j UNIVERSITY OF DEBRECEN   (Hungary)

^k DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^l Srinagarind hospital   (Thailand)

^m AIX MARSEILLE UNIVERSITY   (France)

ⁿ UNIVERSITY OF BERN   (Switzerland)

^o AUCKLAND CITY HOSPITAL   (New Zealand)

^p Asan Medical Center   (South Korea)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

^r CAEN UNIVERSITY HOSPITAL   (France)

^s CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^t CHULABHORN GRADUATE INSTITUTE   (Thailand)

^u Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^v BAYER CORPORATION   (United States)

^w BAYER AG   (Germany)

^x Global Development   (Brazil)

^y MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^z UNIVERSITY OF BARCELONA   (Spain)

^aa INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^ab Division of Gastroenterology   (Austria)

^ac Sungkyunkwan University School of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CIRCULATING TUMOR DNA; CTNNB1 PROTEIN, HUMAN; DIPHENYLAMINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN P53; RAS PROTEIN; SORAFENIB; SULFONAMIDE; TELOMERASE; TERT PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; AGED; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CIRCULATING TUMOR DNA; DIPHENYLAMINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAP KINASE KINASE KINASES; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RAS PROTEINS; SORAFENIB; SULFONAMIDES; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85053740236     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-3588     Document Type: Article

References (42)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-43.
4. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
6. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;[Epub ahead of print].
7. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
8. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol 2018;36:abstr 207.
9. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
10. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70.
11. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/ 2 for the treatment of cancer. Cancer Res 2009;69:6839-47.
12. Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CHR, Stephenson JJ, et al. A Phase I study of the safety, pharmacokinetics, and pharmacodynamics of combination therapy with refametinib plus sorafenib in patients with advanced cancer. Clin Cancer Res 2016;22:2368-76.
13. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48.
14. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-5.
15. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
16. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
17. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2014;20:5976-85.
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
19. Clark TA, Kennedy M, Young L, Zhao M, Coyne M, Breese V, et al. Rigorous validation of clinical circulating tumor DNA for cancer molecular profiling. 107th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, USA, 2016 April 16-20. 3965 ed.
20. Foundation Medicine Inc. FoundationACT technical information. 2016.
21. Wong ALA, Lim JSJ, Sinha A, Gopinathan A, Lim R, Tan CS, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med 2015; 13:57.
22. Hou W, Liu J, Chen P, Wang H, Ye BC, Qiang F. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett 2014;8:1249-54.
23. Turhal NS, Savaş B, Coşkun O, Baş E, Karabulut B, Nart D, et al. Prevalence of K-Ras mutations in hepatocellular carcinoma: a Turkish oncology group pilot study. Mol Clin Oncol 2015;3:1275-9.
24. Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget 2016;7:25087-102.
25. Villanueva A, Llovet JM. Liver cancer in 2013: mutational landscape of HCC - the end of the beginning. Nat Rev Clin Oncol 2014;11:73-4.
26. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108:479-85.
27. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-16.
28. Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Ann Oncol 2016; 27:ii140-ii1.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
30. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011;2:359-72.
31. Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, et al. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. J Clin Oncol (Meeting Abstracts). 2011;29.
32. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013;6:27.
33. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol 2014;11:385-400.
34. Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodere F, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 2012;18:4806-19.
35. Ha Y, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, et al. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget 2016;7:74303-13.
36. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47:505-11.
37. Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopatho-logical significance. Histopathology 2016;70:423-34.
38. Lee SE, Chang SH, Kim WY, Lim SD, Kim WS, Hwang TS, et al. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma. Oncotarget 2016;7:69267-75.
39. Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28: 1756-61.
40. Liu L, Zhao Y, Jia J, Chen H, Bai W, Yang M, et al. The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization. Sci Rep 2016;6:19851.
41. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017;67:999-1008.
42. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEAMing up for detection and quantification of rare sequence variants. Nat Methods 2006;3:95-7.